{"disease":{"id":"hyperplasia","name":"hyperplasia"},"drugs":{"marketed":[{"drug_id":"prednisone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone-phosphate","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"progesterone","indication_name":"Prevention of endometrial hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PROGESTERONE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Progesterone [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"doxazosin-mesylate","indication_name":"Benign Prostatic Hyperplasia (BPH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXAZOSIN MESYLATE","company_name":"","drug_phase":"marketed","molecular_target":"alpha 1 adrenoceptor","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxazosin selectively blocks alpha 1 adrenoceptors, reducing urethral resistance and systemic vascular resistance."},{"drug_id":"alfuzosin-hydrochloride","indication_name":"Benign Prostatic Hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ALFUZOSIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"alpha 1-adrenoreceptors","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Alfuzosin blocks post-synaptic alpha 1-adrenoreceptors in the prostate and bladder areas to relax smooth muscle."},{"drug_id":"terazosin-hydrochloride","indication_name":"Symptomatic Benign Prostatic Hyperplasia (BPH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TERAZOSIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic adrenocortical hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tadalafil","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cialis","generic_name":"tadalafil","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 2 group E member 1, Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Potassium voltage-gated channel subfamily H member 2","drug_class":"Phosphodiesterase 5 Inhibitor [EPC]","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"tamsulosin","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flomax","generic_name":"tamsulosin","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 7, Alpha-1A adrenergic receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"medroxyprogesterone","indication_name":"Endometrial Hyperplasia Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depo-Provera","generic_name":"medroxyprogesterone","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Progesterone receptor","drug_class":"Progestin","quality_score":null,"revenue":null,"mechanism":"Depo-Provera works by binding to the progesterone receptor in the body, which helps to regulate the menstrual cycle and prevent pregnancy."},{"drug_id":"cortisone-acetate","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"doxazosin","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cardura","generic_name":"DOXAZOSIN","company_name":"Viatris","drug_phase":"marketed","molecular_target":"Alpha-1B adrenergic receptor","drug_class":"alpha-Adrenergic Blocker","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"synarel","indication_name":"Exclusion of other causes of sexual precocity, such as congenital adrenal hyperplasia, testotoxicosis, testicular tumors and/or other autonomous feminizing or masculinizing disorders","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Synarel","generic_name":"Nafarelin Acetate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptors","drug_class":"Gonadotropin-releasing hormone agonists","quality_score":67,"revenue":null,"mechanism":"Gonadotropin-releasing hormone agonist medication"},{"drug_id":"aldactone","indication_name":"Long-term maintenance therapy for bilateral micro or macronodular adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"Spironolactone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule","drug_class":"Potassium-sparing diuretic, aldosterone antagonist","quality_score":66,"revenue":null,"mechanism":"Aldosterone antagonist causing increased sodium and water excretion while retaining potassium."},{"drug_id":"endometrin","indication_name":"Endometrial Hyperplasia Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Endometrin","generic_name":"progesterone","company_name":"Ferring","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1","drug_class":"Progesterone [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"cialis","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cialis","company_name":"Ottawa Hospital Research Institute","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 2 group E member 1, Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Potassium voltage-gated channel subfamily H member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"hydrocortisone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"crinecerfont","indication_name":"classic congenital adrenal hyperplasia (CAH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crenessity","generic_name":"CRINECERFONT","company_name":"Neurocrine","drug_phase":"marketed","molecular_target":"","drug_class":"Corticotropin-releasing Factor Type 1 Receptor Antagonist [EPC]","quality_score":56,"revenue":null,"mechanism":"Crenessity blocks the hormone corticotropin-releasing factor, which stimulates the adrenal glands to produce excess hormones."},{"drug_id":"naftopidil","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flivas","generic_name":"NAFTOPIDIL","company_name":"Asahi Kasei","drug_phase":"marketed","molecular_target":"Alpha-1D adrenergic receptor","drug_class":"naftopidil","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"silodosin","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rapaflo","generic_name":"SILODOSIN","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"alpha-1 adrenoreceptors","drug_class":"alpha-Adrenergic Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Silodosin blocks alpha-1 adrenoreceptors in the prostate and bladder, causing smooth muscle relaxation and improving urine flow."},{"drug_id":"diazoxide","indication_name":"Islet cell hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Proglycem","generic_name":"DIAZOXIDE","company_name":"","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"diazoxide","quality_score":55,"revenue":null,"mechanism":"Proglycem works by blocking the ATP-sensitive potassium channel, which helps to increase blood sugar levels and reduce insulin secretion."},{"drug_id":"terazosin","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hytrin","generic_name":"TERAZOSIN","company_name":"","drug_phase":"marketed","molecular_target":"Alpha-1D adrenergic receptor","drug_class":"alpha-Adrenergic Blocker","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"alfuzosin","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Uroxatral","generic_name":"ALFUZOSIN","company_name":"Advanz","drug_phase":"marketed","molecular_target":"alpha 1-adrenoreceptors","drug_class":"alpha-Adrenergic Blocker","quality_score":10,"revenue":null,"mechanism":"Alfuzosin blocks post-synaptic alpha 1-adrenoreceptors in the prostate and bladder areas to relax smooth muscle."},{"drug_id":"methylprednisolone-acetate","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depo-Medrol","generic_name":"METHYLPREDNISOLONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Depo-Medrol works by binding to the glucocorticoid receptor, which then regulates the expression of genes involved in inflammation and immune response."},{"drug_id":"betamethasone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"cortisol","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"terazosine","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Terazosine","company_name":"University of Iowa","drug_phase":"phase_2","molecular_target":"Ribosyldihydronicotinamide dehydrogenase [quinone], Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 2A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"progesteron","indication_name":"Endometrial Hyperplasia Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Progesteron","company_name":"Minia University","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Congenital adrenal hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"avodart","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avodart","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"3-oxo-5-alpha-steroid 4-dehydrogenase 1, 3-oxo-5-alpha-steroid 4-dehydrogenase 2, Glycine receptor subunit alpha-1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dutasteride","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avodart","generic_name":"dutasteride","company_name":"GSK (GlaxoSmithKline)","drug_phase":"marketed","molecular_target":"3-oxo-5-alpha-steroid 4-dehydrogenase 1, 3-oxo-5-alpha-steroid 4-dehydrogenase 2, Glycine receptor subunit alpha-1","drug_class":"5-alpha-reductase inhibitor (dual)","quality_score":null,"revenue":null,"mechanism":"Dual 5-alpha-reductase inhibitor (types I and II) that more completely suppresses DHT than finasteride for BPH treatment."},{"drug_id":"finasteride","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Propecia","generic_name":"finasteride","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1, Cytochrome P450 2C19, Cytochrome P450 2C9","drug_class":"5-alpha-reductase inhibitor","quality_score":null,"revenue":null,"mechanism":"Selective type II 5-alpha-reductase inhibitor that blocks conversion of testosterone to dihydrotestosterone (DHT), treating BPH and male pattern hair loss."}],"pipeline":[],"offLabel":[],"totalMarketed":51,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT07153783","title":"Interventional AI-Human Collaboration for Liver Tumor Diagnosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":10333,"lead_sponsor_name":"Shengjing Hospital","has_results":false},{"nct_id":"NCT07159165","title":"Registry of MIUS for Benign Prostatic Obstruction","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":10000,"lead_sponsor_name":"Ondokuz Mayıs University","has_results":false},{"nct_id":"NCT03354416","title":"Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06182189","title":"Protocollo N 2014 - Benign Prostatic Hyperplasia","phase":"","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT05463796","title":"InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT05422677","title":"An Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia","phase":"","overall_status":"COMPLETED","enrollment_count":4698,"lead_sponsor_name":"Hanmi Pharmaceutical Company Limited","has_results":false},{"nct_id":"NCT07298707","title":"Cervical Cytology DNA Methylation for Endometrial Lesion Screening and Follow-up","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT03382158","title":"International PPB/DICER1 Registry","phase":"","overall_status":"RECRUITING","enrollment_count":3400,"lead_sponsor_name":"Children's Hospitals and Clinics of Minnesota","has_results":false},{"nct_id":"NCT05051722","title":"Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":3110,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT00250159","title":"Natural History Study of Patients With Excess Androgen","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT05697601","title":"Predictors of Ovarian Cancer and Endometrial Cancer for Artificial-Intelligence-Based Screening Tools","phase":"","overall_status":"UNKNOWN","enrollment_count":2905,"lead_sponsor_name":"Hasanuddin University","has_results":false},{"nct_id":"NCT05292235","title":"Perioperative Parameter and Treatment Outcomes of Surgical Treatment for Benign Prostate Hyperplasia in Hong Kong","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT07242807","title":"Minimally Invasive Prostate Interventions Registry (MIST Study)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Necmettin Erbakan University","has_results":false},{"nct_id":"NCT07137299","title":"POPQ Associated With Total Laparoscopic Hysterectomy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Medical University of Silesia","has_results":false},{"nct_id":"NCT04890444","title":"China Adrenal Disease Registry","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT04889469","title":"Indications for Breast Reduction in the Public Health Care System","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Vastra Gotaland Region","has_results":false},{"nct_id":"NCT02757963","title":"Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1679,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06589154","title":"The Application of Multimodal Artificial Intelligence Systems in Prostate Cancer Diagnosis and Prognosis Analysis","phase":"","overall_status":"COMPLETED","enrollment_count":1651,"lead_sponsor_name":"Shanghai Changzheng Hospital","has_results":false},{"nct_id":"NCT03538665","title":"The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT05868252","title":"Molecular Analysis of the Sloane Project","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"King's College London","has_results":false},{"nct_id":"NCT04726748","title":"Economic Evaluation of Prostatic Urethral Lift","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1360,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT04212403","title":"Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB)","phase":"NA","overall_status":"COMPLETED","enrollment_count":1350,"lead_sponsor_name":"Jessa Hospital","has_results":false},{"nct_id":"NCT01018511","title":"Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1334,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":true},{"nct_id":"NCT04831476","title":"Α Prospective Observational Study for the Evaluation of Disease Control and Quality of Life in Patients With Benign PROStatic hyPERplasia Under Fixed Dose combΙnaTion Treatment With Dutasteride and Tamsulosin . PROSPERITY Group of Studies (I&II)","phase":"","overall_status":"COMPLETED","enrollment_count":1296,"lead_sponsor_name":"Elpen Pharmaceutical Co. Inc.","has_results":false},{"nct_id":"NCT01021332","title":"Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1067,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":true},{"nct_id":"NCT07417449","title":"Impact of Long-term Dutasteride Use on Perioperative Outcomes of HoLEP","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Ankara City Hospital Bilkent","has_results":false},{"nct_id":"NCT05178498","title":"Impact of Dietary Inflammatory Potential on Breast Cancer Risk","phase":"","overall_status":"RECRUITING","enrollment_count":960,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT00892866","title":"CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":877,"lead_sponsor_name":"GOG Foundation","has_results":false},{"nct_id":"NCT05717634","title":"Endometrial Changes in Breast Cancer Women.","phase":"","overall_status":"UNKNOWN","enrollment_count":829,"lead_sponsor_name":"Regina Elena Cancer Institute","has_results":false},{"nct_id":"NCT06546735","title":"Efficacy and Safety of Two Fixed-dose Combinations in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. (BENIPRO)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":816,"lead_sponsor_name":"Eurofarma Laboratorios S.A.","has_results":false},{"nct_id":"NCT02972268","title":"Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":780,"lead_sponsor_name":"Jeil Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT00339651","title":"Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":745,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01294592","title":"Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":742,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02757768","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":715,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT03479359","title":"Learning Curve of Digital Rectal Examination for Prostate Cancer Among Internship","phase":"","overall_status":"UNKNOWN","enrollment_count":700,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT04947631","title":"Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":667,"lead_sponsor_name":"Dongkook Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03179670","title":"Interest of a Systematic Assessment of the Treatment of LUTS in the Management of BPH","phase":"","overall_status":"COMPLETED","enrollment_count":625,"lead_sponsor_name":"RECORDATI GROUP","has_results":false},{"nct_id":"NCT02058368","title":"Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":607,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04428827","title":"Outcome of Patients With Primary Aldosteronism","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Changi General Hospital","has_results":false},{"nct_id":"NCT00127179","title":"A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Organon and Co","has_results":false},{"nct_id":"NCT04463316","title":"GROWing Up With Rare GENEtic Syndromes","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"dr. Laura C. G. de Graaff-Herder","has_results":false},{"nct_id":"NCT07357714","title":"Urinary Function and Multimorbidity Risks: A Longitudinal Study in Beijing Community-Dwelling Elderly","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT06560476","title":"OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Urotronic Inc.","has_results":false},{"nct_id":"NCT03554070","title":"Thulium Fiber Laser Enucleation of the Prostate (ThuFLEP): Efficacy and Safety","phase":"NA","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"I.M. Sechenov First Moscow State Medical University","has_results":false},{"nct_id":"NCT06852859","title":"Patient-reported Pain and Symptom Relief During Three Months After Surgery for Benign Prostatic Hyperplasia","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Sahlgrenska University Hospital","has_results":false},{"nct_id":"NCT06272305","title":"TREC - Evaluation of the Impact of Eversion Technical Features on the Rate of Carotid Restenosis","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"University Hospital, Angers","has_results":false},{"nct_id":"NCT03207061","title":"Can 3D Ultrasound be Used as an Alternative to MRI to Assess Myometrial Invasion in Endometrial Cancer?","phase":"NA","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT03521648","title":"Database for the Assessment of Efficacy and Safety of BPH Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Dominik Abt","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}